Clinical Trials

10 enrolled 11 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

118 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence

NCT01576666 2020-12-19

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

BreastCNSGastrointestinal

120 enrolled

Breast Neoplasms, Glioblastoma, Stomach Neoplasms, Colorectal Neoplasms

NCT02154776 2020-12-19

LeeBLet

13 enrolled

Breast Neoplasms

NCT02088684 2020-12-17

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

70 enrolled

Breast Neoplasms

NCT01155453 2020-12-09

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

113 enrolled

BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01626209 2020-12-09

A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors

BreastGastrointestinalThoracic

32 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT01068483 2020-12-08

Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients

BreastGastrointestinalGynecologic

107 enrolled

Breast Neoplasms, Colonic Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT01629615 2020-10-28

A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer

50 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01363232 2020-10-05

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

BreastGastrointestinalGynecologic

89 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01610284 2020-08-25

BELLE-2

Phase 3 Completed

1,147 enrolled 20 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02058381 2020-03-09

B-YOND

40 enrolled

Pre-menopausal Breast Cancer

NCT01816594 2019-11-14

NeoPHOEBE

50 enrolled 23 charts

Breast Neoplasms

NCT01633060 2019-01-30

BELLE-3

Phase 3 Terminated

432 enrolled 20 charts

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT01790932 2019-01-23

BKM120 For Triple Negative Breast Cancer

50 enrolled 8 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01923168 2018-09-14

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

340 enrolled 39 charts

Breast Neoplasms

NCT02404844 2018-04-20

PIKTAM

48 enrolled

Breast Neoplasms

NCT01572727 2017-03-09

BELLE-4

Phase 2/3 Completed

416 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT01339442 2017-01-25

BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer

31 enrolled

Breast Neoplasms

NCT01132664 2016-08-17

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

Phase 1/2 Terminated

72 enrolled 15 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01248494 2016-07-25

PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

72 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms

NCT01501604 2015-09-17

BKM120 in Cancers With PIK3CA Activating Mutations

Phase 2 Withdrawn

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT01953445 2014-12-08

Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer

Phase 2 Withdrawn

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT01513356 2014-04-02

Pharmacodynamic Study of BKM120 in Breast Cancer

20 enrolled